{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:09:15Z","timestamp":1788826155302,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Randomized controlled trials are the foundation of oncology drug development, yet increasing concern exists that some prioritize regulatory approval over outcomes that matter to patients. The Common Sense Oncology (CSO) initiative was founded to reorient research toward patient-valued endpoints. The CSO Patient Priorities Working Group sought to codevelop a pragmatic, patient-centered framework articulating values and actions to guide the design, conduct, and reporting of oncology randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multiphase, mixed-methods process included literature review, thematic analysis, and international stakeholder engagement. Eight focus groups were held between April 2024 and January 2025 with 131 participants across 7 countries, including people with lived cancer experience, advocates, clinicians, and trialists. Feedback from surveys and structured discussions\u2014quantitative ratings and qualitative insights\u2014informed iterative framework refinement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final framework defines 9 core values with associated actions: meaningful research question, patient partnerships, informed consent, meaningful benefit, generalizability, optimal comparator arm, minimal participant burden, timely feedback of results, and clear dissemination. All values received high endorsement (median 8-9 on a 9-point numeric rating scale [from 1 (least important) to 9 (most important)]). Qualitative analysis emphasized meaningful endpoints, transparent communication, equitable inclusion, fair compensation, and plain-language consent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The CSO Values to Action Framework provides a validated, internationally informed structure for trialists, ethics boards, funders, and advocates. It offers a practical tool to align oncology research with what matters most to patients, promoting more ethical, inclusive, and relevant clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag092","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:42:27Z","timestamp":1774615347000},"page":"1648-1656","source":"Crossref","is-referenced-by-count":0,"title":["Common sense oncology values to action: a patient-led framework for randomized clinical trial design"],"prefix":"10.1093","volume":"118","author":[{"given":"Michelle L","family":"Tregear","sequence":"first","affiliation":[{"name":"National Breast Cancer Coalition , Washington, DC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayde\u00e9 C","family":"Verduzco-Aguirre","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran , Mexico City,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3623-1399","authenticated-orcid":false,"given":"Brian","family":"Shkabari","sequence":"additional","affiliation":[{"name":"Division of Cancer Care and Epidemiology, Sinclair Cancer Research Institute , Kingston, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Koven","sequence":"additional","affiliation":[{"name":"Patient and Family Advisory Council, Southeast Regional Cancer Program, Kingston Health Sciences Centre , Kingston, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Scowcroft","sequence":"additional","affiliation":[{"name":"Independent Communications Consultant and Patient Advocate ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viji","family":"Venkatash","sequence":"additional","affiliation":[{"name":"The Max Foundation , Mumbai,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-0497","authenticated-orcid":false,"given":"Michael D","family":"Brundage","sequence":"additional","affiliation":[{"name":"Division of Cancer Care and Epidemiology, Sinclair Cancer Research Institute , Kingston, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6025-776X","authenticated-orcid":false,"given":"Runcie C W","family":"Chidebe","sequence":"additional","affiliation":[{"name":"Project PINK BLUE- Health and Psychological Trust Centre , Abuja,","place":["Nigeria"]},{"name":"Department of Sociology and Gerontology, Miami University , Oxford, OH,","place":["United States"]},{"name":"Scripps Gerontology Center, Miami University , Oxford, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1410-7820","authenticated-orcid":false,"given":"Elizabeth A","family":"Eisenhauer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queen\u2019s University , Kingston, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7444-8594","authenticated-orcid":false,"given":"Bishal","family":"Gyawali","sequence":"additional","affiliation":[{"name":"Division of Cancer Care and Epidemiology, Sinclair Cancer Research Institute , Kingston, ON,","place":["Canada"]},{"name":"Department of Oncology, Queen\u2019s University , Kingston, ON,","place":["Canada"]},{"name":"Department of Public Health Sciences, Queen\u2019s University , Kingston, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-1531","authenticated-orcid":false,"given":"Bhawna","family":"Sirohi","sequence":"additional","affiliation":[{"name":"Vedanta Medical Research Foundation-Balco Medical Centre , Raipur,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-3653","authenticated-orcid":false,"given":"Christopher M","family":"Booth","sequence":"additional","affiliation":[{"name":"Division of Cancer Care and Epidemiology, Sinclair Cancer Research Institute , Kingston, ON,","place":["Canada"]},{"name":"Department of Oncology, Queen\u2019s University , Kingston, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-709X","authenticated-orcid":false,"given":"Christopher G C A","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago , Dunedin,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026090719565236000_djag092-B1","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2008.16.5456","article-title":"Evolution of the randomized controlled trial in oncology over three decades","volume":"26","author":"Booth","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026090719565236000_djag092-B2","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S1470-2045(24)00451-0","article-title":"Common sense oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials","volume":"26","author":"Gyawali","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026090719565236000_djag092-B3","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1016\/S1470-2045(16)30572-1","article-title":"Relevance of randomised controlled trials in oncology","volume":"17","author":"Tannock","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026090719565236000_djag092-B4","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026090719565236000_djag092-B5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.breast.2016.06.005","article-title":"Surrogate end points for overall survival in breast cancer trials: a review","volume":"29","author":"Fiteni","year":"2016","journal-title":"Breast"},{"key":"2026090719565236000_djag092-B6","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"key":"2026090719565236000_djag092-B7","doi-asserted-by":"crossref","first-page":"102947","DOI":"10.1016\/j.esmoop.2024.102947","article-title":"Elements of successful patient involvement in clinical cancer trials: a review of the literature","volume":"9","author":"Shakhnenko","year":"2024","journal-title":"ESMO Open"},{"key":"2026090719565236000_djag092-B8","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/curroncol28020137","article-title":"Patient and patient group engagement in cancer clinical trials: a stakeholder charter","volume":"28","author":"Michaud","year":"2021","journal-title":"Curr Oncol"},{"key":"2026090719565236000_djag092-B9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11606-021-07029-4","article-title":"Operationalizing stakeholder engagement through the Stakeholder-Centric Engagement Charter (SCEC)","volume":"37","author":"Mart\u00ednez","year":"2022","journal-title":"J General Internal Medicine"},{"key":"2026090719565236000_djag092-B10","doi-asserted-by":"crossref","first-page":"e000127","DOI":"10.1136\/esmoopen-2016-000127","article-title":"The European Cancer Patient\u2019s Bill of Rights, update and implementation 2016","volume":"1","author":"Lawler","year":"2016","journal-title":"ESMO Open"},{"key":"2026090719565236000_djag092-B11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/OP.24.00339","article-title":"Defining and measuring financial toxicity in low- and middle-income countries","volume":"21","author":"Raptis","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"2026090719565236000_djag092-B12","doi-asserted-by":"crossref","first-page":"e0000005","DOI":"10.1371\/journal.pgph.0000005","article-title":"Out-of-pocket costs near end of life in low- and middle-income countries: a systematic review","volume":"2","author":"Reid","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2026090719565236000_djag092-B13","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2026090719565236000_djag092-B14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1001\/jamaoncol.2019.3338","article-title":"The value of progression-free survival as a treatment end point among patients with advanced cancer: a systematic review and qualitative assessment of the literature","volume":"5","author":"Raphael","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026090719565236000_djag092-B15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/PPA.S235430","article-title":"Analysis of patient preferences in lung cancer - estimating acceptable tradeoffs between treatment benefit and side effects","volume":"14","author":"Janssen","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"2026090719565236000_djag092-B16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/oncolo\/oyad312","article-title":"Patient priorities concerning treatment decisions for advanced neuroendocrine tumors identified by discrete choice experiments","volume":"29","author":"Anaka","year":"2024","journal-title":"Oncologist"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag092\/67864839\/djag092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/9\/1648\/67864839\/djag092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/9\/1648\/67864839\/djag092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:57:01Z","timestamp":1788825421000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/9\/1648\/8606841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag092","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,30]]}}}